Letter to Congress Announcing Most Favored Patient Initiative
Members of the United States Congress
Capitol Hill
Washington, DC 20515
Dear Members of Congress:
As Congress considers the future of American healthcare, we urge you to support the principles outlined in the Most Favored Patient Healthcare Initiative—a bold, free-market blueprint that puts American patients first and offers a real solution to rising healthcare costs, foreign freeloading, and bureaucratic inefficiencies.
Launched as a project of Unleash Prosperity Now, this initiative builds on the vision and several reforms put forth by President Donald J. Trump and conservative leaders in Congress to drive a bold policy agenda that champions Accountability, Competition, and Transparency (ACT) without abandoning conservative free-market principles or adopting price controls. These principles, if enacted, can help restore patient choice, lower costs, and preserve America’s role as the world leader in medical innovation without copying other countries’ failed health care systems.
The Most Favored Patient Blueprint outlines specific policy solutions to:
Allow direct-to-consumer sales of medicines to bypass insurer-PBM middlemen fees
End foreign free riding on American innovation, manufacturing, and labor
Require foreign countries to pay the same percentage of GDP for innovative medicines as the U.S. pays
Safeguard U.S. economic and national security from adversaries like China, which is trying to replace the U.S. as the world leader in developing innovative medicines
Eliminate waste, fraud, and abuse that harm taxpayers and patients
Lower patient costs while improving the quality of healthcare they receive
We also released new polling from McLaughlin & Associates showing that likely voters in key battleground states strongly support many of the reforms we propose, several of which align with policy priorities already under discussion in Congress and President Trump’s healthcare agenda. Examples include:
86% support allowing U.S. drug manufacturers to sell prescription drugs directly to American patients and local pharmacies to bypass and avoid added costs imposed by health insurance companies and other middlemen
78% support forcing foreign countries to pay their fair share for prescription drugs developed and manufactured by American drug manufacturers and workers through tougher trade negotiations
75% support requiring foreign countries to invest defined levels of investment to ensure American patients, taxpayers and U.S. manufacturers do not bear the vastly disproportionate burden of paying for the development and manufacturing of medicines that are used in other countries
84% support U.S. drug developers and manufacturers who invest in domestic research and development, manufacturing, and U.S. jobs to better compete with China and other foreign competitors
86% support requiring pharmacy benefit manager corporation middlemen to pass on negotiated drug rebates and discounts to patients when paying for their prescription drugs
We believe this is an urgent opportunity to replace harmful federal policies and price controls with patient-driven solutions. Transparency, competition, and accountability must be the foundation of any serious reform effort.
We invite you to review the full policy blueprint, available at www.MostFavoredPatient.org, and would welcome the opportunity to speak with your office about how the MFP Healthcare Initiative can support your legislative priorities.
Thank you for your continued leadership in the effort to protect American patients and preserve our nation’s healthcare leadership.
Sincerely,
Stephen Moore
Dr. Tomas J. Philipson
Steve Forbes
Phil Kerpen
Founders, Most Favored Patient Healthcare Initiative
Unleash Prosperity Now